Rezolute Stock Jumps 4% After Preliminary Trial Results Clear The Study's Main Goal
The rare-disease drug developer also priced approximately $100 million in financing for commercialization preparations and other costs.
Rezolute, which develops treatments for rare disorders that cause dangerously low blood sugar, jumped 4.4% to $4.04 in Friday trading, as of 9:48 AM ET, adding $16 million in market value. The gain followed preliminary results that met the main goal of its late-stage ersodetug trial, according to the company's Friday SEC filing.
13 Responders Clear A Nine-Patient Threshold
Intravenous glucose needs fell by at least 50% for 13 of the 16 participants with tumor-related low blood sugar. The study required nine responders to meet its main goal, and 12 stopped infusions entirely.
Three participants remain in the pivotal treatment period. Rezolute expects final study results, with statistical analysis, by mid-December.
The preliminary findings extend an earlier result: seven of eight participants in the study's first half responded and stopped intravenous glucose. The remaining participant stopped the study drug to pursue hospice care at home and died from cancer progression. Rezolute counted that participant as a non-responder.
Friday's advance put RZLT shares on pace for their fourth gain of 3% or more this month. At Thursday's close, the stock was up 64% year to date against the S&P 500's 11% gain, despite a 21% decline over the previous month.
Financing For An Unapproved Drug
Rezolute also priced an offering of shares and pre-funded warrants expected to generate approximately $100 million. It plans to use the proceeds for ersodetug commercialization preparations, working capital and general corporate purposes.
The company has no approved products. Ersodetug is an intravenous antibody being studied for excess insulin activity caused by tumors and for congenital hyperinsulinism, which affects children. Rezolute also supplies the drug through an expanded-access program for patients unable to join a trial.
Rezolute reported a quarterly net loss of $18.5 million for the period ended September 30, compared with $18.2 million a year earlier. Cash, cash equivalents and marketable investments fell to $90 million from $107.8 million at June 30.
Research and development spending was $12.8 million, versus $13.1 million a year earlier. General and administrative costs were $6.6 million, versus $6.7 million.
A Separate Approval Path For Children
Rezolute plans to submit an FDA approval application for ersodetug in 2027 for one or potentially both conditions. In October, the FDA recommended an application for the congenital condition after a meeting with the company, according to its November 5 update.
The congenital trial missed its main goal because reductions in low-blood-sugar events measured by finger-stick testing were not statistically significant against placebo. Rezolute said continuous glucose monitoring showed clinically relevant improvements, and its ongoing trial extension showed better glucose control and reduced use of background treatments.
An FDA recommendation to apply leaves approval pending. Rezolute cautioned that the agency might not find the evidence sufficient to approve ersodetug for the congenital condition.
Rezolute expects the financing to close on or about Monday. The completed tumor-study analysis is expected by mid-December.
Sources
- https://www.sec.gov/Archives/edgar/data/1509261/000110465926126499/tm2627558d8_fwp.htm — sec.gov
- tm2627558-6_424b5 - none - 4.6136843s — sec.gov
- Rezolute Announces Pricing of Approximately $100 Million — globenewswire.com
- Rezolute Announces Positive Results from the Phase 3 upLIFT — globenewswire.com
- The company's filing (Rezolute) — SEC filing
- Rezolute — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR
- Rezolute — earnings release (Form 8-K, Item 2.02), filed 2026-11-05 — SEC EDGAR